key: cord-0886972-1t2hje1m
authors: Mestres, Gaspar; Puigmacià, Roger; Blanco, Carla; Yugueros, Xavier; Esturrica, Montserrat; Riambau, Vincent
title: Risk of peripheral arterial thrombosis in COVID-19
date: 2020-05-07
journal: J Vasc Surg
DOI: 10.1016/j.jvs.2020.04.477
sha: 54c87dccbcd7f57f5c84d811f2ff4f6370cdd6c5
doc_id: 886972
cord_uid: 1t2hje1m

nan

Since the report of the first COVID-19 cases in Wuhan (China) on December 31, 2019, several thrombotic complications associated with this disease have been described. 1, 2 These have mainly included venous thromboembolic events 3 and myocardial infarction. 4 However, we have noted a rapidly increasing occurrence of a not previously described vascular complication in critically ill patients: acute peripheral arterial thrombosis.

To date, in our institution (Hospital Clinic, Barcelona, Spain; a reference center for COVID-19 treatment), we have diagnosed acute limb ischemia in four patients infected with COVID-19 that was attributed to the secondary hypercoagulable state. Of the four patients, three had presented with infrapopliteal arterial thrombosis of all distal vessels in one or both legs (one and two patients, respectively; Fig). The fourth patient had presented with femoral-popliteal, and radial-ulnar arterial thrombosis. All four patients had associated distal cutaneous microembolism of the toes or fingers, with progressive distal clinical onset of symptoms: toe or finger dysesthesia and paresis, without muscular infarct. The mean patient age was 71 years. The four patients (three men) had had no previous severe comorbidities or known cardiovascular disease that could have caused the arterial embolisms. Acute ischemia had appeared on average 15 days after the onset of respiratory COVID-19 symptoms. All four patients had previously been admitted to intensive care units because of severe respiratory syndrome, with high oxygen and dedicated treatment requirement (lopinavir/ritonavir, hydroxychloroquine, corticosteroids, azithromycin, anticoagulation, and, eventually, tocilizumab or plasma exchange). Only one case had presented with coexisting venous thromboembolism and splenic infarct. The blood samples revealed an average high D-dimer (>10,000 ng/mL), lactate dehydrogenase (823 U/L), and ferritin (2473 ng/mL) levels, with moderate elevation of C-reactive-protein, platelets, and leukocytosis, and decreased mean coagulation times.

Of the four cases, two underwent surgery. One patient had undergone open bilateral popliteal direct thrombectomy of all distal vessels, and one had undergone open femoral-popliteal and radial-ulnar thrombectomy. Both patients recovered immediate patency of all declotted arteries and experienced improved clinical symptoms, despite the finding of segmental distal asymptomatic rethrombosis at 24 hours after surgery (plantar arch or one of the distal infrapopliteal vessels). The other two patients did not undergo surgery because of their extremely poor respiratory condition and relatively welltolerated ischemia; these patients have continued to receive follow-up.

The vascular community should be aware of this new thrombotic complication in critically ill patients with COVID-19. It can be due to the hypercoagulable secondary status, and surgery is a valuable treatment option for complicated cases, despite the risk of rethrombosis.

Hematological findings and complications of COVID-19

COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET)

Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series

Cardiovascular considerations in treating patients with coronavirus (COVID-19)

Fig. Angiography computed tomography three-dimensional reconstruction of 3 cases of infrapopliteal arterial thrombosis.